Anebulo Pharmaceuticals, Inc. (ANEB)
PNK · Healthcare · Biotechnology
$0.33
-7.00%
Closing price as of 2026-09-10 · Source: TEK2day Finance
Key Metrics
Market Cap
$13.5M
Shares Outstanding
40.8M
Exchange
PNK
Currency
USD
About Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
Quarterly Financials
| Metric | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (1.5M) | (2.2M) | (2.3M) | (2.1M) |
| Net Income | (1.7M) | (2.1M) | (2.2M) | (2.0M) |
| Diluted EPS | $-0.04 | $-0.05 | $-0.05 | $-0.05 |
Annual Financials
| Metric | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (6.8M) | (11.8M) | (8.3M) | (8.4M) |
| Net Income | (6.8M) | (11.7M) | (8.2M) | (8.5M) |
| Diluted EPS | $-0.29 | $-0.47 | $-0.32 | $-0.25 |